JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

LeMaitre Vascular Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

92.55 0.92

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

90.39

Max

93.14

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-173K

11M

Pardavimai

4.2M

60M

P/E

Sektoriaus vid.

41.151

34.393

Pelnas, tenkantis vienai akcijai

0.48

Dividendų pajamingumas

0.84

Pelno marža

18.391

Darbuotojai

651

EBITDA

-7.5M

13M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+13.06% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.84%

2.54%

Kitas uždarbis

2025-10-30

Kitas dividendų mokėjimo data

2025-09-04

Kita Ex Dividend data

2025-08-21

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-166M

1.9B

Ankstesnė atidarymo kaina

91.63

Ankstesnė uždarymo kaina

92.55

Naujienos nuotaikos

By Acuity

50%

50%

162 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

LeMaitre Vascular Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-11 17:49; UTC

Pagrindinės rinkos jėgos

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025-08-11 17:18; UTC

Pagrindinės rinkos jėgos

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025-08-11 16:25; UTC

Uždarbis

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025-08-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025-08-11 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025-08-11 23:32; UTC

Rinkos pokalbiai

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025-08-11 23:02; UTC

Rinkos pokalbiai

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025-08-11 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement 2Q Rev $25.8M >EXOD

2025-08-11 20:14; UTC

Rinkos pokalbiai

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025-08-11 19:12; UTC

Rinkos pokalbiai

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025-08-11 18:56; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025-08-11 18:31; UTC

Rinkos pokalbiai

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025-08-11 17:43; UTC

Rinkos pokalbiai

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025-08-11 17:28; UTC

Rinkos pokalbiai

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025-08-11 17:16; UTC

Rinkos pokalbiai

Commodity Longs Fall to 11-Month Low -- Market Talk

2025-08-11 16:42; UTC

Įsigijimai, susijungimai, perėmimai

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025-08-11 16:27; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Says Sabadell Offer Remains in Effect

2025-08-11 16:26; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Announced TSB Sale on July 1

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Akcijų palyginimas

Kainos pokytis

LeMaitre Vascular Inc Prognozė

Kainos tikslas

By TipRanks

13.06% į viršų

12 mėnesių prognozė

Vidutinis 104.33 USD  13.06%

Aukščiausias 113 USD

Žemiausias 95 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines LeMaitre Vascular Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

5

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

78.565 / 91.76Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

162 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę LeMaitre Vascular Inc

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.